Amyris (AMRS) Misses Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- S&P 500, Nasdaq futures decline as US-Iran escalation rattles sentiment
- Oil gains over 2% as fresh military strikes threaten Hormuz shipments
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Apple sues OpenAI, two former employees for trade secrets theft
AMYRIS, INC. REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
August 9, 2022 8:00 AM EDTRecord consumer revenue of $43 million increased 108% compared to Q2 2021Ingredients sold out in first half with $15 million backlog to be supplied in H2Cost actions and price increases to deliver $50 million of EBITDA improvements in H2$700 million non-equity funding and earnout provides liquidity to sustained profitability
EMERYVILLE, Calif., Aug. 9, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM... More
